Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas. Structurally it is a polycationic aminoglycoside built on a deoxystreptamine core with multiple amino and hydroxyl substituents, conferring high water solubility and poor oral bioavailability. The drug exerts bactericidal activity by binding to the 30S ribosomal subunit, disrupting initiation and elongation of protein synthesis and promoting misincorporation of amino acids. Clinically tobramycin is formulated for parenteral administration, inhalation solutions for respiratory infections including cystic fibrosis, and topical ophthalmic preparations. Pharmacokinetics are characterized by limited tissue penetration beyond extracellular fluid, primary renal elimination of unchanged drug, and a short plasma half-life in patients with normal renal function; dose modification and therapeutic drug monitoring are commonly used for systemic therapy to reduce risk of nephrotoxicity and ototoxicity. In manufacturing and formulation contexts tobramycin is handled as a hygroscopic, polar API that requires validated microbiological and potency controls and stability assessment in aqueous matrices.
Parent: Tobramycin
Parent: Tobramycin
Typical quality control and pharmacopoeial specifications for tobramycin API and finished products focus on assay, related substances, and specific known degradants. Common related compounds and impurities observed from fermentation, isolation, and degradation pathways include epimeric isomers, N-oxide derivatives, deaminated species, ring-opened glycoside fragments and minor aminoglycoside co-products from the producing organism. Typical commercial and regulatory specification ranges used by manufacturers are assay within approximately 90 to 110 percent of label claim; total related substances not greater than about 5.0 percent; any single identified or unidentified related compound not greater than about 1.0 percent; and stricter limits for specified degradants such as certain epimers or N-oxides often set at 0.5 to 1.0 percent. Final product specifications vary by monograph and regulatory authority and should be confirmed against the applicable pharmacopeial or regulatory dossier for the marketed formulation.
Tobramycin is used to treat infections caused by susceptible aerobic Gram-negative bacteria, including Pseudomonas aeruginosa; it is used systemically for serious infections, by inhalation for chronic Pseudomonas airway infection in cystic fibrosis, and topically as ophthalmic drops or ointment for bacterial eye infections.
Topical ophthalmic tobramycin is an effective option for many bacterial conjunctival and superficial ocular infections caused by susceptible organisms; it is a prescription product and selection should be based on likely pathogens and local resistance patterns; it does not treat viral or fungal eye infections.
Patients with a known hypersensitivity to aminoglycoside antibiotics should not use tobramycin; systemic use requires caution or dose adjustment in renal impairment and in patients with preexisting hearing loss because of ototoxicity risk, and aminoglycosides can worsen neuromuscular weakness so use is cautioned in myasthenia gravis and similar conditions.
